Avadel Pharmaceuticals Initiates Definitive Proxy Statement Dispatch
Avadel Pharmaceuticals plc, known for its innovative biopharmaceutical solutions, has taken a significant step as it begins mailing the Definitive Proxy Statement to its shareholders. This move is crucial as part of the Proposed Transaction involving Alkermes plc, whereby the latter aims to acquire Avadel’s entire issued ordinary share capital.
Details of the Proposed Transaction
Avadel and Alkermes have previously outlined their agreement under Rule 2.7 of the Irish Takeover Rules. The plan is to implement this acquisition using a scheme of arrangement as defined under the Irish Companies Act 2014. This will ensure a structured and compliant transition as both companies move forward.
Understanding the Scheme
The Scheme, as it pertains to the Proposed Transaction, requires shareholders to actively engage in the upcoming Scheme Meeting and Extraordinary General Meeting (EGM). The Definitive Proxy Statement serves as an essential circular that outlines the terms to be considered by Avadel shareholders. An exciting time is ahead as shareholders prepare to discuss the future of the company.
Scheduled Meetings for Shareholders
Scheduled for January 12, 2026, the Scheme Meeting will commence promptly at 10:00 a.m. (Irish local time), followed by the EGM at 10:15 a.m. (or immediately after the Scheme Meeting if it runs over). Both meetings will take place at the offices of Arthur Cox LLP in Dublin, creating an avenue for shareholders to raise questions and vote on the proposed acquisition.
What’s Inside the Definitive Proxy Statement?
This important document not only contains the full terms of the Proposed Transaction but also provides crucial information required under Irish Company law. It includes guidelines on how Avadel shareholders should proceed, ensuring clarity and transparency throughout this important process.
About Avadel Pharmaceuticals
Avadel Pharmaceuticals plc, listed on NASDAQ as AVDL, is committed to transforming the lives of patients through innovative medicines. One of its notable products, LUMRYZ™, was approved as the first once-at-bedtime oxybate for extended-release oral suspension targeting narcolepsy in patients aged seven and above, showcasing the company’s dedication to addressing unmet medical needs.
Those interested in learning more about Avadel’s initiatives can explore its official website, which highlights the company’s mission and ongoing projects.
Keeping Investors Informed
In keeping with its commitment to transparency, Avadel has shared essential contact information for investor relations, ensuring shareholders can stay informed and engaged. For any inquiries, shareholders can reach out to Avadel Investor Relations via email.
Important Reminders for Shareholders
As the Company navigates this transition, Avadel emphasizes the importance of informed shareholder participation in the impending meetings. Engaging with the Definitive Proxy Statement thoroughly will enable shareholders to make well-informed decisions regarding the future of their investments.
Frequently Asked Questions
What is the purpose of the Definitive Proxy Statement?
The Definitive Proxy Statement provides detailed information regarding the Proposed Transaction, including the terms and conditions that Avadel shareholders need to consider during the upcoming meetings.
When will the shareholder meetings take place?
The Scheme Meeting and the Extraordinary General Meeting (EGM) are scheduled for January 12, 2026, starting at 10:00 a.m. (Irish local time).
What should shareholders review before the meetings?
Shareholders are encouraged to read the Definitive Proxy Statement thoroughly to understand the Proposed Transaction and prepare for the vote.
What is Avadel’s main product related to?
Avadel’s main product, LUMRYZ™, is designed for the treatment of narcolepsy and is a once-at-bedtime oxybate solution approved by the U.S. FDA.
How can investors stay updated on the acquisition?
Investors can stay updated through Avadel’s official website and by contacting investor relations for any queries related to the acquisition process.
